Gilead opportunities in HIV underappreciated, says Oppenheimer

December 5, 2012

Oppenheimer believes that Gilead has several underappreciated opportunities related to the fixed dose combinations of its HIV treatments. As a result, the firm thinks the company could generate more cash flow from its HIV treatments than is currently anticipated, and it reiterates an Outperform rating on the stock.